Fermer le menu

The future of Antimicrobial Resistance Fighting

IMPACT2 – a Eurostars project

Project

The IMPACT2AMR consortium combines the complementary expertise of three highly experienced partners, BioVersys, BioSystems Technology, and Voxcan, to develop novel translational research tools.

 

The consortium aims to generate a translational research platform to promote the development of antimicrobials and anti-virulence drugs – from the bench to in vivo proof-of-concept.

Business

Current drug discovery tools are inadequate to address MDR/XDR pathogens, requiring development of alternative strategies to be able to explore and target these problematic pathogens. IMPACT2AMR aims to deliver a single research platform that is composed of three independent sub-components, which will be used to expedite development of antimicrobials and novel anti-virulence drugs.